Oritavancin Diphosphate
FDA-approved product (powder, intravenous), marketed as Kimyrsa, Orbactiv.
- Registered studies
- 7
- Lab records
- 2
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
- Skin disease caused by bacterial infection
- Soft Tissue Infections
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Glycopeptide antibacterials
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01XA05
Repurposing investigation
Oritavancin Diphosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli72.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae75.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
7registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Oritavancin Diphosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PlecanatideExisting use: Constipation52.2% AI-predicted activityagainst K. pneumoniae15 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
NCT03873987 · start 2019-07-16
Registered record
- Registry ID
- NCT03873987
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Interventions
- Current Formulation of Oritavancin; Kimyrsa
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-07-16
- Completion
- 2019-09-04
- Enrolment
- 102
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Bacterial Skin and Skin Structure InfectionInterventionCurrent Formulation of Oritavancin; KimyrsaPhasePhase 1Registry statusCompletedDrug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
NCT02340988 · start 2015-04
Registered record
- Registry ID
- NCT02340988
- Conditions
- Healthy
- Interventions
- Single-Dose IV Oritavancin Diphosphate and Warfarin; Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2015-09
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSingle-Dose IV Oritavancin Diphosphate and Warfarin; Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dosePhasePhase 1Registry statusCompletedOpen Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
NCT02134301 · start 2014-05
Registered record
- Registry ID
- NCT02134301
- Conditions
- Gram-positive Bacterial Infections
- Interventions
- Oritavancin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-05
- Completion
- 2025-11-04
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGram-positive Bacterial InfectionsInterventionOritavancinPhasePhase 1Registry statusCompletedOpen Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
NCT01784536 · start 2013-01
Registered record
- Registry ID
- NCT01784536
- Conditions
- Healthy
- Interventions
- Single-Dose IV Oritavancin Diphosphate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2013-03
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSingle-Dose IV Oritavancin DiphosphatePhasePhase 1Registry statusCompletedA Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
NCT01762839 · start 2012-12-27
Registered record
- Registry ID
- NCT01762839
- Conditions
- Healthy
- Interventions
- Single-Dose IV Oritavancin Diphosphate; Placebo; Moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-12-27
- Completion
- 2013-02-11
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSingle-Dose IV Oritavancin Diphosphate; Placebo; MoxifloxacinPhasePhase 1Registry statusCompletedOritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
NCT01252719 · start 2010-12
Registered record
- Registry ID
- NCT01252719
- Conditions
- Wound Infection; Abscess; Systemic Inflammation; Cellulitis
- Interventions
- Single-Dose IV Oritavancin Diphosphate; IV Vancomycin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2012-11-30
- Enrolment
- 968
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWound Infection; Abscess; Systemic Inflammation; CellulitisInterventionSingle-Dose IV Oritavancin Diphosphate; IV Vancomycin; PlaceboPhasePhase 3Registry statusCompletedOritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
NCT01252732 · start 2010-12
Registered record
- Registry ID
- NCT01252732
- Conditions
- Wound Infection; Abscess; Systemic Inflammation; Cellulitis
- Interventions
- Single-Dose IV Oritavancin Diphosphate; IV Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2013-06
- Enrolment
- 1,019
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionWound Infection; Abscess; Systemic Inflammation; CellulitisInterventionSingle-Dose IV Oritavancin Diphosphate; IV VancomycinPhasePhase 3Registry statusCompleted